Nobivac NXT® HCPChFeLV
Combination vaccine for cats against feline herpesvirus (FHV), feline calicivirus (FCV), feline panleucopaenia virus (FPL), Chlamydia felis and feline leukaemia virus (FeLV).
Nobivac NXT® HCPChFeLV delivers broad protection against core diseases and FeLV, plus additional coverage against Chlamydia felis in a single low-volume, adjuvant-free dose. 1 – 3 years of immunity* gives you the choice and flexibility to tailor protocols to each cat’s lifestyle and risk level.
Cats at risk of exposure to these very common and widespread threats benefit from vaccination with this next-generation Nobivac® combination vaccine.
Key Features
- Low-volume doses (0.5 mL)
- Adjuvant-free formulations
- Innovative RNA particle technology for FeLV in cats
- Rapid 1-week onset of immunity (OOI)
- 1 – 3-year duration of immunity (DOI)*
- Proven safety profile for kittens and cats†
- Approved for concurrent (non-mixed) use with Nobivac® Rabies
- Real-world results‡
* All viral components offer 1 – 3 years of immunity. Chlamydia felis has a 1-year DOI.
† First dose from 8 weeks of age.
‡ Nobivac NXT® HCPChFeLV has been administered in cats across North America since 2024.
Presentation
Off-white or cream-coloured lyophilisate and clear colourless solvent for suspension.
Active ingredients
Nobivac NXT® HCPChFeLV is a live attenuated vaccine.§
Each dose (0.5 mL) of reconstituted vaccine contains:
- Live attenuated feline herpesvirus type 1, strain G2620A: 105.8 – 107.1 plaque forming units (PFU)
- Live attenuated feline calicivirus, strain F9: 104.6 – 107.0 PFU
- Live attenuated feline panleucopaenia virus, strain MW-1: 105.2 – 106.4 TCID₅₀||
- Live attenuated feline Chlamydia felis strain Baker: 104.1 – 107.0 TCID₅₀||
- Feline leukaemia virus glycoprotein RNA-particle (RP): 106.6 – 109.3 RP
§ The FeLV component is a self-amplifying RNA particle vaccine.
|| Tissue culture infective dose 50%
Indications for use
Nobivac NXT® HCPChFeLV is indicated for active immunisation of cats:
- To reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV).
- To reduce the clinical signs and virus excretion caused by infection with feline calicivirus (FCV).
- To prevent mortality, clinical signs, leucopaenia and virus excretion caused by infection with feline panleucopaenia virus (FPL).
- To reduce the clinical signs and bacterial excretion caused by infection with Chlamydia felis (Ch).
- To prevent/reduce persistent viraemia and clinical signs caused by feline leukaemia virus (FeLV).
Onset of immunity: 1 week.
Duration of immunity:
- For feline herpesvirus type 1: 1 year after primary vaccination, 1 – 3 years after re-vaccination.
- For feline calicivirus: 1 year after primary vaccination, 1 – 3 years after re-vaccination.¶
- For feline panleucopaenia virus: 1 – 3 years.
- For Chlamydia felis: 1 year.
- For feline leukaemia virus: 1 year after primary vaccination, 1 – 3 years after re-vaccination.
¶ Until 1 year after primary vaccination or re-vaccination, a prevention in persistent viraemia and in clinical signs associated with feline leukaemia virus has been demonstrated.
Contra-indications
None.
Warnings
Only vaccinate healthy animals.
Special precautions for safe use in the target species: The presence of maternally derived antibodies may interfere with the efficacy of the vaccine.
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV-positive cats is of no benefit.
Vaccinated cats may excrete the feline herpesvirus and feline calicivirus vaccine strains from the respiratory tract for 14 days following vaccination. Vaccinated cats may excrete the feline panleucopaenia virus vaccine strain in the faeces for 14 days following vaccination.
The viruses can spread to other cats, but without causing clinical signs of disease.
Do not use during pregnancy.
Side effects
Cats:
Common (1–10 animals / 100 animals treated): Injection site swelling,# elevated temperature.**
Very rare (<1 animal / 10,000 animals treated, including isolated reports): Febrile limping syndrome reactions in kittens.††
# 0.5–2 cm, diffuse, hard or soft, not warm and can be painful, lasting for 1 day.
** Pyrexia (≥39.7 °C) lasting for 1 day.
†† Can occur in kittens, as reported after the use of any vaccine containing a feline calicivirus component. Transient.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinary healthcare professional, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Administration routes and dosage
For subcutaneous use.
Reconstitute the vial containing the lyophilisate with the supplied solvent. Ensure that the lyophilisate is completely reconstituted before use. Administer the total contents of the vial.
Reconstituted product: off-pink or pink-coloured suspension.
Vaccination schedule:
Primary vaccination: The first vaccination can be administered from 8 weeks of age, and the second vaccination 3-4 weeks later.
Re-vaccination:
- A single dose, administered at up to 1 year after primary vaccination, maintains protection against feline herpesvirus type 1, feline calicivirus and feline leukaemia virus. For subsequent revaccinations, a single dose should be administered at intervals of 1 – 3 years.
- A single dose, administered at intervals of up to 1 – 3 years after primary vaccination or re-vaccination with this vaccine maintains protection against feline panleucopaenia virus.
- A single dose, administered at intervals of up to 1 year after primary vaccination or re-vaccination with this vaccine maintains protection against Chlamydia felis.
Withdrawal periods
Not applicable.
Special precautions for storage
Lyophilisate:
Store and transport refrigerated (2°–8 °C).
Do not freeze.
Protect from light.
Solvent:
No special precautions for storage.
Classification of veterinary medicinal products
Prescription decisions are for the person issuing the prescription alone.
Authorisation numbers and pack sizes
EU/2/26/365/001-002
Available in 5×1 dose and 25×1 dose packs.
Not all pack sizes may be marketed
Legal categories
POM (ROI) POM-V (NI)
FAQs
What diseases does Nobivac NXT® HCPChFeLV protect against?
Nobivac NXT® HCPChFeLV protects against:
- feline herpesvirus type 1 (FHV)
- feline calicivirus (FCV)
- feline panleucopaenia virus (FPL)
- Chlamydia felis
- feline leukaemia virus (FeLV)
What is the duration of immunity for Nobivac NXT® HCPChFeLV?
Nobivac NXT® HCPChFeLV provides 1 – 3 years of immunity against
- feline herpesvirus (FHV)
- feline calicivirus (FCV)
- feline panleucopaenia virus (FPV)
- feline leukaemia virus (FeLV)
Chlamydia felis has a 1-year duration of immunity.
What is the onset of immunity for Nobivac NXT® HCPChFeLV?
Nobivac NXT® HCPChFeLV provides a 1-week onset of immunity following completion of the primary 2-dose vaccination series.
Can Nobivac NXT® HCPChFeLV be given at the same time with other Nobivac vaccines?
Nobivac NXT® HCPChFeLV is approved for concurrent (non-mixed) use with Nobivac® Rabies.
Can Nobivac NXT® HCPChFeLV be used in pregnancy?
Do not use during pregnancy.
What are the storage requirements for Nobivac NXT® HCPChFeLV?
Lyophilisate:
- Store and transport refrigerated (2°C–8°C)
- Do not freeze
- Protect from light
Solvent:
- No special storage precautions
Unanswered question?
Email your question and our team will reply within 2 business days.